Gabather AB (publ) (GABA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gabather AB (publ) (GABA) has a cash flow conversion efficiency ratio of 1.858x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.86 Million ≈ $-522.80K USD) by net assets (Skr-2.61 Million ≈ $-281.31K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gabather AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Gabather AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GABA liabilities breakdown for a breakdown of total debt and financial obligations.
Gabather AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gabather AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suumaya Industries Limited
NSE:SUULD
|
-0.016x |
|
Cake Box Holdings PLC
LSE:CBOX
|
0.097x |
|
INFINITII AI INC.
F:Y31
|
N/A |
|
POLAREAN IMAG.LS-00037
F:8ZF
|
N/A |
|
HTC Purenergy Inc.
V:HTC
|
0.006x |
|
Inspecs Group plc
LSE:SPEC
|
0.071x |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
0.000x |
|
Trifast plc
LSE:TRI
|
0.049x |
Annual Cash Flow Conversion Efficiency for Gabather AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Gabather AB (publ) from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Gabather AB (publ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr-4.17 Million ≈ $-449.30K |
Skr-3.33 Million ≈ $-358.15K |
0.797x | +103.33% |
| 2023-12-31 | Skr486.00K ≈ $52.30K |
Skr-11.64 Million ≈ $-1.25 Million |
-23.957x | -758.22% |
| 2022-12-31 | Skr3.44 Million ≈ $369.98K |
Skr-9.60 Million ≈ $-1.03 Million |
-2.791x | -89.90% |
| 2021-12-31 | Skr10.96 Million ≈ $1.18 Million |
Skr-16.12 Million ≈ $-1.73 Million |
-1.470x | -209.74% |
| 2020-12-31 | Skr28.85 Million ≈ $3.10 Million |
Skr-13.69 Million ≈ $-1.47 Million |
-0.475x | -51.21% |
| 2019-12-31 | Skr43.59 Million ≈ $4.69 Million |
Skr-13.68 Million ≈ $-1.47 Million |
-0.314x | +75.16% |
| 2018-12-31 | Skr15.87 Million ≈ $1.71 Million |
Skr-20.05 Million ≈ $-2.16 Million |
-1.264x | -497.58% |
| 2017-12-31 | Skr45.76 Million ≈ $4.92 Million |
Skr-9.68 Million ≈ $-1.04 Million |
-0.211x | +0.97% |
| 2016-12-31 | Skr33.19 Million ≈ $3.57 Million |
Skr-7.09 Million ≈ $-762.54K |
-0.214x | +50.12% |
| 2015-12-31 | Skr12.79 Million ≈ $1.38 Million |
Skr-5.47 Million ≈ $-588.95K |
-0.428x | -141796.96% |
| 2014-12-31 | Skr8.63 Million ≈ $929.25K |
Skr-2.60K ≈ $-280.32 |
0.000x | -- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more